Physician profile
Jonathan Calvert
NPI 1033793724
$1,999.07
in general payments reported to CMS, 2019-2025
20 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $848 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.49 | 2024-2025 | |
| Pfizer INC. | $208.29 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $154.43 | 2025 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.58 | 2024-2025 | Jardiance |
| Viiv Healthcare Company | $115.93 | 2023-2025 | Apretude |
| Astellas Pharma US INC | $76.26 | 2024-2025 | Veozah |
| Lilly USA, LLC | $70.85 | 2024-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $68.06 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $62.94 | 2024-2025 | Otezla, Repatha, Otezla |
| Gilead Sciences, INC. | $59.49 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.65 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $34.45 | 2024-2025 | Korlym |
| Inspire Medical Systems, INC. | $32.69 | 2025 | Inspire |
| Lundbeck LLC | $28.62 | 2025 | Vyepti |
| Dynavax Technologies Corporation | $27.66 | 2025 | Heplisav-B |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $25.71 | 2024 | Azstarys |
| Radius Health, INC. | $21.00 | 2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $17.18 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.25 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.